CeriBell logo

CeriBell

CBLL | NASDAQ
Chart Builder DCF Calculator
$26.42
+$0.28 (+1.07%)
At close: Nov 16, 2026, 4:00 PM ET
$26.42
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
+1.07%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
40.5
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #513/1021 (Top 50%)

Key Statistics

Market Data

Market Cap $1.03B
1D Range
25.60 26.46
52W Range
12.89 28.27

Valuation (TTM)

PE -13.62
PB 8.73
EV/EBITDA -13.11

Valuation (NTM)

Forward PE N/A
Forward PEG -0.36
Price Target $27.50
Loading financial charts...

Profile

CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions direc...

Sector Healthcare
Employees 327
IPO Date Oct 11, 2024
Fiscal Year January - December

Latest News

CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue Estimates

13 days ago · zacks.com

CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue Estimates
CeriBell, Inc. (CBLL) Q3 2026 Earnings Call Transcript

13 days ago · seekingalpha.com

CeriBell, Inc. (CBLL) Q3 2026 Earnings Call Transcript
Compared to Estimates, CeriBell, Inc. (CBLL) Q3 Earnings: A Look at Key Metrics

13 days ago · zacks.com

Compared to Estimates, CeriBell, Inc. (CBLL) Q3 Earnings: A Look at Key Metrics
CeriBell Q3 Earnings Call Highlights

13 days ago · marketbeat.com

CeriBell Q3 Earnings Call Highlights
Ceribell Reports Third Quarter 2026 Financial Results

13 days ago · globenewswire.com

Ceribell Reports Third Quarter 2026 Financial Results
Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution

15 days ago · globenewswire.com

Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

19 days ago · globenewswire.com

Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Earnings

Latest Earnings
Nov 3, 2026
EPS
-$0.55
Miss -7.84%
REV
$29.34M
Beat +0.56%
Next Earnings
Feb 23, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
3
Consensus
Buy
Price Target
$27.50
Upside
+4.09%
Buy (3)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.